Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis
dc.contributor.author | Checchi, F | |
dc.contributor.author | Funk, S | |
dc.contributor.author | Chandramohan, D | |
dc.contributor.author | Haydon, D T | |
dc.contributor.author | Chappuis, F | |
dc.date.accessioned | 2015-07-15T19:08:53Z | |
dc.date.available | 2015-07-15T19:08:53Z | |
dc.date.issued | 2015-07-04 | |
dc.identifier.citation | Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis., 8 (1):292 BMC Res Notes | en_GB |
dc.identifier.issn | 1756-0500 | |
dc.identifier.pmid | 26140922 | |
dc.identifier.doi | 10.1186/s13104-015-1244-3 | |
dc.identifier.uri | http://hdl.handle.net/10144/560514 | |
dc.description.abstract | The duration of the stages of HAT is an important factor in epidemiological studies and intervention planning. Previously, we published estimates of the duration of the haemo-lymphatic stage 1 and meningo-encephalitic stage 2 of the gambiense form of human African trypanosomiasis (HAT), in the absence of treatment. Here we revise the estimate of stage 2 duration, computed based on data from Uganda and South Sudan, by adjusting observed infection prevalence for incomplete case detection coverage and diagnostic inaccuracy. | |
dc.language | ENG | |
dc.language.iso | en | en |
dc.publisher | BMC | en_GB |
dc.rights | Archived with thanks to BMC Research Notes and Open Access | en_GB |
dc.title | Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis | en |
dc.identifier.journal | BMC Research Notes | en_GB |
refterms.dateFOA | 2019-03-04T12:27:14Z | |
html.description.abstract | The duration of the stages of HAT is an important factor in epidemiological studies and intervention planning. Previously, we published estimates of the duration of the haemo-lymphatic stage 1 and meningo-encephalitic stage 2 of the gambiense form of human African trypanosomiasis (HAT), in the absence of treatment. Here we revise the estimate of stage 2 duration, computed based on data from Uganda and South Sudan, by adjusting observed infection prevalence for incomplete case detection coverage and diagnostic inaccuracy. |